[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-kidney-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-kidney-injury":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,196,0,25,[9,55,82,115,142,177,198,220,238,260,279,302,325,353,377,397,427,452,471,496,523,548,571,598,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100652603","finerenone-for-aki-a-multicenter-randomized-placebo-controlled-feasibility-pilot-trial-100652603",false,"NCT07775482","Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial","Finerenone to Improve Acute Kidney Injury; a Multicenter, Randomized, Placebo-Controlled Study to Investigate the Feasibility of Finerenone in Treating Patients With Acute Kidney Injury (FiPAKI Pilot Trial)","FiPAKI","Inclusion Criteria:\n\n* Adult patients (≥18 years old) at the time of giving consent\n* Admitted to the hospital at the time of giving consent\n* KDIGO Stage ≥2 AKI confirmed by at least two separate creatinine measurements (definition: ≥2.0 times baseline creatinine, no urine output criteria)\n* Sustained AKI criteria for ≥48 hours since AKI diagnosis\n* No AKI progression before randomization (as per the judgement of the investigator)\n* Serum potassium ≤4.8 mmol\u002FL within 48 hours before randomization\n* Suspected intrinsic AKI (hemodynamic and obstructive AKI has been ruled out according to the judgment of the investigator)\n* Participant should be capable of giving signed informed consent, which includes compliance with the requirements and restrictions of the participating site\n\nExclusion Criteria:\n\n* Planned hospital discharge within 48 hours\n* Any ongoing use of MRA (spironolactone, eplerenone, finerenone), potassium-sparing diuretics (such as triamterene or amiloride), or potassium binders\n* Advanced CKD defined as eGFR ≤30 mL\u002Fmin\u002F1.73m² or undergoing KRT at baseline\n* Ongoing KRT at the time of randomization (Stage 3-dialysed AKI that partially\u002Fcompletely recovered and no longer required KRT at randomization can be included)\n* Clinically unstable (based on investigator clinical evaluation, i.e., vasopressors, uncontrolled sepsis)\n* Confirmed or suspected glomerular disease (other than diabetes) or acute interstitial nephritis requiring immunosuppressive therapy as the primary cause of AKI\n* Previous hypersensitivity to finerenone\n* Documented history of adrenal insufficiency or Addison's disease\n* Concomitant therapy with strong CYP3A4 inhibitors, if conversion to another medication is not feasible\n* Clinician judgment that the intervention is contraindicated due to: A) risk of hyperkalemia; B) risk of KRT initiation within the next 7 days (anuria or rapid increase in serum creatinine); C) impossibility to administer potassium binders\n* Enrollment in another clinical trial that could impact potassium, GFR, or kidney function\n* For women who are able to become pregnant: positive pregnancy test and\u002For being breastfeeding at screening\n* Any other condition or therapy, in the judgement of the Investigator or the Sponsor, which could make the participant unsuitable for this study, including a condition or therapy which the Investigator anticipates will not allow participation for the full planned study period (i.e., condition limiting life expectancy to less than 3 months)","ALL","18 Years",{"count":21,"type":22},72,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI). This study will explore whether finerenone can mitigate the risk of transitioning to chronic kidney disease following a moderate to severe AKI. Participants will be randomly assigned to receive either finerenone or a placebo, once daily for up to 45 days, in addition to their standard care. The study will monitor for side effects such as serum potassium levels and blood pressure, and will assess whether the drug helps prevent AKI from progressing to chronic kidney disease. This is a pilot feasibility study involving approximately 72 participants across 4-5 sites in Quebec and Ontario.",[28,29,30],"Acute Kidney Injury","Renal Insufficiency,Chronic","Kidney Diseases",[32,33,34,35,36,37,38,39,40,41],"Finerenone","Acute kidney injury","AKI to CKD transition","Chronic kidney disease","Renal fibrosis","Mineralocorticoid receptor antagonist","Hyperkalemia","Pilot study","Feasibility trial","Nephroprotection","NOT_YET_RECRUITING","2026-08-17",{"date":45,"type":46},"2026-08-20","ACTUAL",{"date":48,"type":22},"2027-01",{"date":50,"type":22},"2030-01",{"name":52,"class":53},"Jean-Maxime Côté","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100588124","phase-2-droxidopa-to-increase-mean-arterial-pressure-in-decompensated-cirrhosis-patients-with-acute-kidney-injury-100588124","NCT06937307","Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury","DROP-AKI","Inclusion Criteria:\n\n* Ability to provide informed consent by subject or legally authorized representative\n* Consent to blood and urine collection for biomarker analysis\n* Ability to take oral medications\n* At least 18 years of age\n* Hospitalized at Columbia University Irving Medical Center\n* Child-Pugh Score ≥ B7 cirrhosis (documented by imaging, biopsy, or clinical evidence)\n* KDIGO Stage 1 AKI or greater, defined as:\n* ≥0.3 mg\u002FdL increase in serum creatinine within 48 hours OR\n* ≥50% increase in serum creatinine from outpatient baseline\n* Mean arterial pressure ≤85 mmHg averaged over 24 hours prior to randomization\n* For women of childbearing potential: negative pregnancy test and agreement to use effective contraception\n\nExclusion Criteria:\n\n* Serum creatinine \\>4.0 mg\u002FdL or current renal replacement therapy\n* Age \\>70 years\n* Severe cardiovascular disease, including:\n* Unstable angina\n* Congestive heart failure requiring escalating medical therapy\n* Symptomatic peripheral vascular disease\n* Any cardiovascular condition deemed severe by investigator\n* Active gastrointestinal bleeding, defined as requiring ≥ 2 units of packed red blood cells during the screening period\n* Acute respiratory failure requiring more than 6L of Nasal Canula\n* Use of medications that could interact with droxidopa including:\n* MAOI inhibitors\n* Norepinephrine reuptake inhibitors\n* Other investigational drugs\n* Pregnancy or breastfeeding\n* Any episode of a SBP ≥ 180 mmHg or a DBP ≥ 120 mmHg on two measurements, 1 minute apart\n* Prior liver transplantation","70 Years",{"count":64,"type":22},75,[66],"PHASE2","This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospitalized with cirrhosis and kidney injury. Participants will take either droxidopa or placebo pills for 28 days and be monitored for an additional 30 days. Researchers will measure changes in blood pressure and kidney function to determine if droxidopa is effective and safe for these patients. This research could identify a new treatment option for a serious complication of liver disease.",[28,69,70],"Cirrhosis","Decompensated Cirrhosis of Liver",[28,69,72],"Decompensated Cirrhosis","RECRUITING",{"date":75,"type":46},"2026-08-19",{"date":77,"type":46},"2025-05-27",{"date":79,"type":22},"2028-12-31",{"name":81,"class":53},"Giuseppe Cullaro, MD",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":112,"locationsCount":114},"100635701","phase-4-the-vancomycin-piperacillintazobactam-vpt-patient-safety-trial-vps-100635701","NCT07556107","The Vancomycin Piperacillin\u002FTazobactam (VPT) Patient Safety Trial (VPS)","A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin\u002FTazobactam or Meropenem: VPT Patient Safety (VPS) Study","VPS","Inclusion criteria\n\n1. Hospitalized or being hospitalized.\n2. Age \\>\u002F=18 yr old.\n3. Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician.\n4. Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively).\n5. Consenting\u002Fenrollment will not clinically significantly delay abx administration.\n6. Baseline and \\>\u002F=1 prior Scr available (within 1 yr).\n7. Pt or LAR able to provide IC. Exclusion criteria\n\n1\\. AKI (\\>\u002F=moderate) (KDIGO stage 2-3) (Scr increase \\>\u002F=2-fold from chronic BL) (Scr based).\n\n2\\. CKD (\\>\u002F=moderately to severely decreased eGFR) (KDIGO stage G3b-G5) (by history or eGFR \\\u003C\u002F=44 mL\u002Fmin\u002F1.73M2) (Scr based).\n\n3\\. Beta lactam allergy. 4. Contraindication to VPT or VM. 5. Infection requiring VPT or VM specifically or another abx regimen. 6. Participation in another research study with interventions that may impact study endpoints.",{"count":91,"type":22},852,[93],"PHASE4","The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.",[96,28,97],"Infection","Sepsis",[99,100,101,102,103,104,105,106],"infection","hospitalized","AKI","cystatin c","vancomycin","piperacillin\u002Ftazobactam","meropenem","RCT","2026-08-16",{"date":109,"type":46},"2026-08-18",{"date":43,"type":22},{"date":79,"type":22},{"name":113,"class":53},"Bassett Healthcare",3,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":138,"leadSponsor":140,"locationsCount":54},"100651887","clinical-characteristics-and-in-hospital-outcomes-of-critically-ill-patients-receiving-hemodialysis-or-continuous-venovenous-hemodiafiltration-in-the-emergency-department-100651887","NCT07765030","Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department","Evaluation of Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Undergoing Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department","Inclusion Criteria:\n\n* Age 18 years or older.\n* Followed in the critical care area of the Emergency Department of Antalya\n* Training and Research Hospital between January 1, 2023, and August 1, 2026.\n* Presence of an indication for emergency renal replacement therapy.\n* Underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the emergency department.\n* Required critical care-level monitoring or management.\n* Availability of sufficient demographic, clinical, laboratory, and in-hospital outcome data in the hospital information system, electronic medical records, laboratory records, or clinical follow-up notes.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Renal replacement therapy initiated outside the emergency department.\n* Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.\n* Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.\n* Missing essential clinical, laboratory, or in-hospital outcome data. In patients with repeated emergency department admissions, only the first emergency renal replacement therapy episode will be included to reduce statistical dependency.",{"count":123,"type":22},150,"OBSERVATIONAL","This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.\n\nMedical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor\u002Finotropic support, intensive care unit admission, length of stay, and hospital outcomes.\n\nThe primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor\u002Finotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.",[28,127,128],"Kidney Failure, Acute","Kidney Failure",[130,131,132,28,133],"Emergency Renal Replacement Therapy","Hemodialysis","Continuous Venovenous Hemodiafiltration","In-Hospital Mortality","2026-08-10",{"date":136,"type":46},"2026-08-14",{"date":134,"type":22},{"date":139,"type":22},"2026-11-01",{"name":141,"class":53},"Antalya Health Sciences University",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":152,"conditions":153,"keywords":159,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100651477","erector-spinae-oxygen-saturation-and-aki-after-opcab-100651477","NCT07760129","Erector Spinae Oxygen Saturation and AKI After OPCAB","Erector Spinae Muscle Oxygen Saturation as an Early Predictor of Acute Kidney Injury in Patients Undergoing Off-Pump Coronary Artery Bypass Surgery","Inclusion Criteria:\n\n1. Adults aged 19 years or older scheduled for elective off-pump coronary artery bypass (OPCAB) surgery.\n2. Able to receive a full explanation of the purpose and procedures of the study and to provide written informed consent voluntarily.\n3. Depth from the skin to the erector spinae muscle at the level of the left renal hilum, measured by ultrasonography in the operating room before anesthetic induction, of less than 2.0 cm, so that stable near-infrared spectroscopy measurement is considered feasible. Consenting patients who do not meet this criterion are not enrolled and are classified as screen failures.\n\nExclusion Criteria:\n\n1. Emergency surgery.\n2. Concomitant surgery performed by another department.\n3. Preoperative or postoperative cardiogenic shock, or need for mechanical circulatory support.\n4. Estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m2.\n5. Previous kidney transplantation.\n6. Left renal disease or a solitary kidney.\n7. Body mass index above 30 kg\u002Fm2.\n8. Active bleeding or active infection.\n9. Inability to read and voluntarily consent to the informed consent document (for example, because of illiteracy, language barrier, or cognitive impairment).\n10. Refusal to participate in the study.","19 Years",{"count":151,"type":22},138,"Acute kidney injury (AKI) is a frequent and serious complication after cardiac surgery, including off-pump coronary artery bypass (OPCAB). Because AKI is diagnosed on the basis of serum creatinine, which rises 1 to 2 days after the actual renal insult, early detection and timely intervention remain difficult. Near-infrared spectroscopy (NIRS) allows non-invasive and continuous measurement of regional tissue oxygen saturation, but the effective penetration depth of commercially available devices is only approximately 2 to 2.5 cm. In most adults the renal cortex lies deeper than this, so the signal obtained from a flank sensor may originate largely from the abdominal wall musculature rather than from renal parenchyma. This limitation may explain the inconsistent association between renal regional oxygen saturation (renal rSO2) and AKI reported so far.\n\nThe erector spinae muscle at the level of the renal hilum lies within 2 cm of the skin in most patients and is supplied by the lumbar arteries and by vessels adjacent to the renal hilum. Erector spinae muscle regional oxygen saturation (ESrSO2) may therefore provide a technically more reliable NIRS signal that reflects perfusion of a vascular territory close to that of the kidney, particularly during the transient low cardiac output state induced by mechanical displacement of the heart for coronary anastomosis during OPCAB.\n\nThis single-center prospective observational cohort study will enroll 138 adult patients scheduled for elective OPCAB at Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. ESrSO2 and renal rSO2 will be measured continuously with an INVOS oximeter from before anesthetic induction until the end of surgery, in addition to cerebral rSO2, which is part of standard care at the participating institution. The ESrSO2 and renal rSO2 channels will be physically masked on the monitor display during surgery, no alarms will be set for these two channels, and their values will not be used for any intraoperative clinical decision. The recorded data will be extracted after surgery using the INVOS Analytics Tool. Apart from placement of the additional NIRS sensors and a brief pre-induction ultrasound measurement of tissue depth, no study-specific procedure, laboratory test, or imaging study will be performed, and all anesthetic, surgical, and postoperative care will follow the standard institutional protocol.\n\nThe primary objective is to identify which ESrSO2-derived variable best predicts postoperative AKI, defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria within 7 days after surgery. The candidate variables are the baseline value, the intraoperative nadir, the area under the threshold (AUT), and the duration under the threshold below absolute values of 60%, 55%, and 50% and below 80% of the baseline value, calculated separately for the period before cardiac displacement and for the cardiac displacement period. Secondary objectives are to assess whether the selected ESrSO2 variable provides independent and incremental predictive information beyond a pre-specified baseline risk model, to compare the predictive performance of ESrSO2 with that of cerebral rSO2 and renal rSO2, and to evaluate the prediction of severe AKI (KDIGO stage 2 to 3) and persistent AKI (lasting 48 hours or longer).\n\nIf ESrSO2 proves to be a useful early marker of AKI, it could allow real-time, non-invasive identification of patients at high risk during surgery and provide a basis for future trials of renal protective strategies.",[28,154,155,156,157,158],"Coronary Artery Disease","Coronary Artery Bypass, Off-Pump","Postoperative Complications","Cardiac Surgical Procedures","Spectroscopy, Near-Infrared",[160,161,162,163,164,165,166,167],"rector spinae muscle regional oxygen saturation (ESrSO2)","near-infrared spectroscopy (NIRS)","regional oxygen saturation (rSO2","off-pump coronary artery bypass (OPCAB)","acute kidney injury (AKI)","KDIGO","area under the threshold (AUT)","tissue oximetry","2026-08-06",{"date":170,"type":46},"2026-08-12",{"date":172,"type":22},"2026-10-01",{"date":174,"type":22},"2029-12-31",{"name":176,"class":53},"Yonsei University",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100650713","pronephro-ngal-test-for-early-detection-of-acute-kidney-injury-in-adult-icu-patients-alpaca-100650713","NCT07751913","ProNephro NGAL Test for Early Detection of Acute Kidney Injury in Adult ICU Patients (ALPACA)","Validation of the ProNephro AKITM (NGAL) in Adult ICU Patients in the ICU at Risk of Moderate to Severe Acute Kidney Injury (ALPACA)","ALPACA","Inclusion Criteria:\n\nMales and females ≥ 22 years of age. Subjects must be admitted or admission pending to an Intensive Care Unit and must have a urine sample collected within 24 hours of ICU admission.\n\nSubjects must have at least one of the following, leading to admission to the ICU, or occurring within 24 hours of admission to the ICU (unless otherwise specified):\n\nVasoactive medication administration Mechanical ventilation Hypoxemia requiring oxygen support therapy including Bilevel positive airway pressure (BIPAP) and high flow nasal canula Serum Lactate greater than 2.5 mmol\u002FL, within 6 hours prior to enrollment History (any) of solid organ transplantation, renal transplantation included only if more than 3 months prior History (any) of bone marrow transplantation Ability to provide written informed consent\n\nExclusion Criteria:\n\nSpecial populations including pregnant and lactating women, prisoners, or institutionalized individuals.\n\nSubjects receiving Kidney Replacement Therapy in the first 24 hours of ICU admission.\n\nSubjects diagnosed with active Urinary Tract Infection per institute standard of care at the time of NGAL sampling.\n\nSubjects with a known history of chronic kidney disease stages 4 or 5 as evidenced by a pre-enrollment estimated GFR of less than 30 mL\u002Fmin\u002F1.73m2.\n\nSubjects with any known urothelial, urological or kidney malignancies.\n\nSubjects that have had any of the following urologic procedure or urologic surgery within 30 days prior to ICU admission:\n\nNephrostomy or nephroureteral stent placement Ureteral stent placement or exchange Ureteroscopy Lithotripsy Transurethral resection of the prostate Transurethral resection of bladder tumor Renal biopsy Subjects that have had surgical nephrectomy less than 3 months prior to admission.\n\nSubjects that have been previously enrolled in this study. Subjects enrolled in an interventional pharmaceutical or device clinical trial ICU admission.","22 Years",{"count":187,"type":22},800,"The purpose of this study is to evaluate the performance of the ProNephro AKI™ (NGAL) test for identifying critically ill adults at risk of developing moderate to severe acute kidney injury (KDIGO Stage 2\u002F3) within 48 to 72 hours of ICU admission.\n\nThe study will assess how accurately the test predicts acute kidney injury by evaluating its sensitivity, specificity, positive predictive value, and negative predictive value. Participants will provide blood and urine samples for testing.",[28],{"date":134,"type":46},{"date":192,"type":22},"2026-08",{"date":194,"type":22},"2028-05",{"name":196,"class":197},"BioPorto Diagnostics","INDUSTRY",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":18,"minAge":205,"maxAge":19,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":54},"100393485","a-study-of-facilitators-and-barriers-to-improve-acute-kidney-injury-in-children-through-mobile-health-intervention-100393485","NCT04403633","A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention","Improving Patient-Centered Care in Pediatric Acute Kidney Injury (Change Peds AKI)","Inclusion Criteria:\n\n* age 1 to 18 years\n* patients with diagnosis of AKI while hospitalized\n\nExclusion Criteria:\n\n* legal blindness of deafness\n* cognitive impairment that limits ability to consent\n* non-English speaking\n* patient age greater than age 18 years, 11 months","1 Year",{"count":7,"type":22},[25],"The purpose of this study is to improve patient-centered care for acute kidney injury (AKI) in order to decrease the adverse health outcomes associated with this common condition.",[28],[101,211,28],"Pediatric AKI",{"date":213,"type":46},"2026-08-07",{"date":215,"type":46},"2020-06-01",{"date":217,"type":22},"2026-12",{"name":219,"class":53},"Duke University",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":4},"100648198","early-postoperative-l-arginine-and-acute-kidney-injury-after-cardiac-surgery-100648198","NCT07718373","Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery","Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery: a Target Trial Emulation","Inclusion Criteria:\n\n·adults admitted to the ICU after CPB-assisted cardiac surgery\n\nExclusion Criteria:\n\n* congenital heart disease,\n* surgery requiring deep hypothermic circulatory arrest,\n* a preoperative baseline estimated glomerular filtration rate (eGFR) below 30 mL\u002Fmin\u002F1.73 m²,\n* AKI already present prior to ICU admission",{"count":228,"type":22},5000,"Acute kidney injury (AKI) is common after cardiac surgery, yet effective protective strategies remain limited. L-arginine is the substrate for endogenous nitric oxide (NO) synthesis and may improve renal perfusion and endothelial function. investigators emulated a target trial to evaluate whether early perioperative L-arginine was associated with a lower risk of AKI after cardiac surgery.",[28],"2026-08-05",{"date":134,"type":46},{"date":234,"type":22},"2026-07-20",{"date":45,"type":22},{"name":237,"class":53},"Xijing Hospital",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":54},"100650775","a-prospective-observational-study-to-evaluate-the-safety-and-feasibility-of-continuous-renal-replacement-therapy-with-regional-citrate-anticoagulation-in-a-cohort-critical-ill-patients-with-acute-kidney-injury-and-presumed-absent-citrate-metabolism-100650775","NCT07751874","A Prospective, Observational Study to Evaluate the Safety and Feasibility of Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation in a Cohort Critical Ill Patients With Acute Kidney Injury and Presumed Absent Citrate Metabolism","CAT-RISK","Inclusion Criteria:\n\n* Need for renal replacement therapy in the ICU with any of the following criteria:\n* anticipation of severely impaired citrate metabolism (serum lactate ≥ 5 mmol\u002Fl in patients with shock or requirement of a dextrose drip to prevent hypoglycemia or spontaneous INR \\> 3 and\u002For requirement of fresh frozen plasma to maintain INR \\\u003C 3 in patients with cirrhosis or acute liver failure or acute on chronic liver failure)\n* development of citrate toxicity under CRRT with RCA due to worsening citrate metabolism\n\nExclusion Criteria:\n\n* Pregnancy\n* A known hypersensitivity to citrate compounds\n* Refusal of informed consent",{"count":246,"type":22},50,"Use of regional citrate anticoagulation in an at risk population with decreased citrate metabolism. This study assesses the feasibility and safety of regional citrate anticoagulation in this population.",[28],[33,250,251],"Regional citrate anticoagulation","citrate metabolism","2026-08-03",{"date":213,"type":46},{"date":255,"type":22},"2026-10-15",{"date":257,"type":22},"2028-07-01",{"name":259,"class":53},"University Hospital, Antwerp",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":54},"100650538","perioperative-transcutaneous-fluorescence-detection-of-gfr-trajectory-for-the-early-prediction-and-diagnosis-of-csa-aki-100650538","NCT07749417","Perioperative Transcutaneous Fluorescence Detection of GFR Trajectory for the Early Prediction and Diagnosis of CSA-AKI.","Establishment and Validation of an Early Warning Model for Acute Kidney Injury During the Perioperative Period of Cardiovascular Diseases.","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Specific inclusion criteria for the cohort:\n\n   * GFR trajectory characterization after cardiovascular surgery or Iodine contrast agent exposure: Patients scheduled for elective cardiovascular surgery or interventional cardiovascular surgery or CTA; ② GFR trajectory characterization of AKI: Patients with confirmed CSA-AKI or contrast-associated acute kidney injury (CA-AKI).\n\nExclusion Criteria:\n\n1. Received renal replacement therapy before surgery or before contrast imaging, including kidney transplantation and regular dialysis;\n2. Serum creatinine \\> 353 μmol\u002FL before surgery or before contrast imaging;\n3. Patients with AKI who did not recover before surgery or before contrast imaging;\n4. Patients with malignant tumors.",{"count":268,"type":22},436,"brief summary：The goal of this observational study is to evaluate the value of perioperative transcutaneous fluorescence glomerular filtration rate (GFR) monitoring for the early prediction and diagnosis of cardiac surgery-associated acute kidney injury (CSA-AKI) and contrast-associated acute kidney injury(CA-AKI) in adult patients. The main questions it aims to answer are: Can perioperative GFR or peri-contast trajectories measured by a transcutaneous fluorescence monitoring system predict the development of CSA-AKI or CA-AKI before conventional diagnostic criteria are met? What changes in perioperative or peri-contast GFR trajectories are associated with the occurrence and severity of CSA-AKI or CA-AKI? Participants scheduled for cardiovascular surgery or contast-enhanced CT scan or PCI will undergo continuous perioperative transcutaneous GFR monitoring following intravenous administration of a fluorescent tracer. Clinical characteristics, perioperative or peri-contast hemodynamic data, laboratory measurements, imaging findings, and postoperative or post-contast outcomes will be collected to evaluate the predictive and diagnostic performance of perioperative or peri-contrast GFR trajectories for CSA-AKI or PC-AKI.",[28],{"date":168,"type":46},{"date":273,"type":46},"2026-07-17",{"date":275,"type":22},"2029-07",{"name":277,"class":278},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100649812","nad-supplementation-to-reduce-the-incidence-of-cardiac-surgery-associated-acute-kidney-injury-100649812","NCT07739290","NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Undergoing coronary artery bypass graft (CABG) and\u002For valve surgery with cardiopulmonary bypass (CPB) at BIDMC. Includes combination surgeries that involve CABG and\u002For valve plus other procedures (e.g., Maze procedure, aortic aneurysm repair).\n3. AKI risk score ≥6 at the time of screening\n\nExclusion Criteria:\n\n1. History of AKI in the seven days prior to surgery, defined as any of the following:\n\n   * Increase in serum creatinine ≥0.3 mg\u002Fdl in 48h\n   * Increase in serum creatinine ≥50% in 7d (if no value available in last 7d, use most recent value in last 3 months)\n   * Urine output ≤0.5 ml\u002Fkg\u002Fh x 6 consecutive hours (only assessed in patients with hourly monitoring via Foley catheter)\n   * Receipt of renal replacement therapy (RRT) within 7d\n2. Advanced chronic kidney disease (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2 or end-stage kidney disease receiving RRT)\n3. Pregnant or breastfeeding\\*\n4. Positive COVID test in the last 10 days.\n5. Prisoner or institutionalized\n6. Existing or anticipated durable VAD\n\n8\\. Conflict with other studies\n\n9\\. Previous usage of nicotinamide supplements in the past 30 days",{"count":286,"type":22},20,[25],"The purpose of this single-center, randomized, double-blinded placebo-controlled pilot trial is to demonstrate feasibility and help design a larger trial to assess the effectiveness of nicotinamide (NAM) supplementation in reducing risk of post-operative AKI in patients undergoing cardiac surgery.",[28],[33,291,292],"nicotinamide adenine dinucleotide","cardiac surgery","2026-07-29",{"date":295,"type":46},"2026-07-31",{"date":297,"type":22},"2026-09-01",{"date":299,"type":22},"2029-01-01",{"name":301,"class":53},"Beth Israel Deaconess Medical Center",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":21},"100609524","phase-2-a-study-to-investigate-the-efficacy-safety-and-tolerability-of-azd4144in-participants-with-sepsis-associated-acute-kidney-injury-100609524","NCT07215702","A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.","A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)","SERENIA","Inclusion Criteria Age ≥ 18 to ≤ 80 years at the time of signing the informed consent. Participants who are admitted to an ICU or an equivalent critical-care unit.\n\nDiagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on:\n\nA. Suspected or confirmed bacterial infection AND B. Acute increase of mSOFA score of 2 or more excluding renal component (change in score measured to account for participants that may meet mSOFA criteria from pre-existing organ dysfunction before the onset of infection).\n\nHaemodynamic therapy:\n\nA. 30 mL\u002Fkg or clinically appropriate volume resuscitation prior to randomisation.\n\nB. Vasopressor and\u002For inotrope therapy for sepsis-induced hypotension (eg, norepinephrine \\[noradrenaline\\], epinephrine \\[adrenaline\\], phenylephrine, dopamine, dobutamine) for ≥ 4 hours.\n\nDiagnosis of AKI, within 72 hours of sepsis diagnosis, with modified KDIGO Stage ≥ 1, defined as: Increase in SCr to ≥ 1.5 × baseline (outpatient \\[preferred\\] or admission pre-AKI reference). Timing of AKI diagnosis is defined as the time that the initial qualifying SCr was reported. AKI must persist after completion of initial volume resuscitation (30 mL\u002Fkg or as clinically indicated per investigator discretion).\n\nOutpatient pre-AKI reference eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2, if available within 2 weeks to 12 months prior to admission (preferred). If not available, admission pre-AKI reference eGFR ≥ 45 mL\u002Fmin\u002F1.73 m2 .\n\nBody weight ≥ 40 kg or ≤ 125 kg. Female or male, assigned at birth, inclusive of all gender identities. All FOCBP must have a negative pregnancy test at the Screening visit (Visit 1).\n\nContraception:\n\nA. Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods detailed in CSP from the time of first administration of study intervention administration until 100 days after the last dose of study intervention.\n\nB. FOCBP must not be lactating and must agree to use an approved method of highly effective contraception, as detailed in the CSP from the time of first administration of study intervention until 100 days after last dose of study intervention.\n\nCapable of giving signed informed consent (participant or LAR). Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research.\n\nExclusion Criteria Any clinical evidence which in the investigator's opinion makes it undesirable for the potential participant to enrol in the study.\n\nKnown history of Stage 4 or 5 CKD with documented sustained eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 prior to hospital admission.\n\nSepsis diagnosed \\> 7 days after hospital admission (to include from time of outside admission if patient transferred from another healthcare setting).\n\nAKI attributed to causes other than sepsis, including but not limited to compromised renal perfusion-related causes (surgical complication, acute abdominal aortic aneurysm, dissection, renal artery stenosis, etc), glomerular disease, acute interstitial nephritis, and medication toxicity.\n\nEvidence of recovery from AKI prior to randomisation defined as:\n\nA. A reduction of SCr to less than 1.5 times reference SCr in the last available local SoC laboratory result before randomisation or B. A \\> 25% reduction in SCr from peak SCr after volume resuscitation prior to randomisation.\n\nExpected survival from sepsis \\\u003C 24 hours. Expected survival \\\u003C 90 days due to chronic or pre-existing medical conditions other than SA-AKI Known history of renal transplant or bilateral nephrectomy. Permanent incapacitation. Incapacitation is defined as the inability to independently perform tasks essential to personal health and\u002For safety.\n\nActive cancer or cancer in remission for less than 2 years. Known history of immunodeficiency disease or currently receiving immunosuppressant therapy for non-sepsis related disease.\n\nSevere burns requiring ICU treatment. Sepsis attributed to confirmed or presumed fungal or viral infection at time of Screening.\n\nHas advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C).\n\nKnown history of cerebrovascular accident within the last 90 days. Known history of heart failure with reduced ejection fraction with documented ejection fraction ≤ 20% before sepsis diagnosis.\n\nKnown hypersensitivity to iohexol or known history of severe adverse reaction to iodinated contrast media.\n\nParticipants with known medical or psychological condition(s), or who, in the judgement of the investigator, should not participate in the study if they are unlikely to comply with study procedures, restrictions, and requirements.\n\nCurrent KRT (eg, continuous haemofiltration and haemodialysis\u002Fcontinuous kidney replacement therapy, intermittent haemodialysis, and peritoneal dialysis) or planned KRT (meaning KRT is scheduled, or the decision to initiate KRT has been made by the treating physician) at randomisation.\n\nCurrently receiving active treatment for malignancy.\n\nPotential participants will be excluded if they have received a certain class of medication during the weeks before enrollment or are anticipated to require a specific class of medication during the trial duration.\n\nParticipants with a known hypersensitivity to AZD4144 or any of the excipients of the product.\n\nReceipt of another IMP within 30 days, 5 half-lives, or the time frame of expected PD effect from most recent dose, whichever is longest.\n\nPrevious receipt of AZD4144. Active or planned treatment of sepsis with an extracorporeal haemoperfusion device.\n\nParticipation in any other concurrent ICU study which could impact participant clinical outcomes and confound results of this study to, including but not limited to volume resuscitation, vasopressor, or mechanical ventilation studies.\n\nPresence of anuria (≥ 12 hours) at randomisation. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead ECG, at Screening, as judged by the investigator.\n\nProlonged QTcF \\> 470 ms. Known history of QT prolongation associated with other medications that required discontinuation of that medication.\n\nCongenital long QT syndrome. Known history of ST-elevation myocardial infarction or non-ST-elevation myocardial infarction, with or without intervention by percutaneous coronary intervention or coronary artery bypass grafting within the last 90 days.\n\nVentricular arrhythmia requiring treatment. Known or presumed latent or active tuberculosis. Acute pancreatitis with no established source of infection. Undergoing extracorporeal membrane oxygenation (ECMO) at randomisation. Neutropenia: ANC \\\u003C 1.5 × 109\u002FL. Admitting diagnosis of rhabdomyolysis. Admitting diagnosis of trauma with CK \\> 15000 U\u002FL. Presumed nidus of infection in central nervous system. Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site).\n\nPrevious randomisation in the present study. For females only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.\n\nFirst infusion of IMP unable to be started within 36 hours of AKI diagnosis. Presence of a do-not-resuscitate order.","80 Years",{"count":312,"type":22},124,[66],"This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.",[97,28],[97,28],{"date":318,"type":46},"2026-07-30",{"date":320,"type":46},"2026-02-10",{"date":322,"type":22},"2027-02-11",{"name":324,"class":197},"AstraZeneca",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":334,"conditions":335,"keywords":340,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":54},"100617905","impact-of-intraoperative-hemodynamic-instability-on-outcomes-in-cardiac-surgery-100617905","NCT07324694","Impact of Intraoperative Hemodynamic Instability on Outcomes in Cardiac Surgery","Impact of Intraoperative Hemodynamic Instability on Postoperative Major Adverse Events in Cardiac Surgery Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Scheduled for elective cardiac surgery (CABG, Valve replacement\u002Frepair, or combined procedures).\n* Surgery performed under cardiopulmonary bypass (CPB).\n* Preoperative sinus rhythm.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Emergency or salvage surgery.\n* Off-pump coronary artery bypass grafting.\n* Preoperative mechanical circulatory support (IABP, ECMO) requirement.\n* Pre-existing chronic renal failure requiring dialysis (HD\u002FPD).\n* Pre-existing cognitive impairment, dementia, or history of psychiatric disorders affecting cooperation.\n* Pregnancy.",{"count":333,"type":22},230,"Intraoperative hemodynamic instability (IOHI) is a common occurrence during cardiac surgery and is associated with organ hypoperfusion. However, the specific impact of IOHI on composite adverse outcomes remains unclear. This prospective cohort study aims to evaluate the association between intraoperative hemodynamic instability (defined as MAP \\\u003C 65 mmHg or vasopressor requirement) and major postoperative complications (Delirium, Acute Kidney Injury, Stroke, or Mortality) in adult patients undergoing elective cardiac surgery with cardiopulmonary bypass.",[336,337,338,28,339],"Cardiac Surgery","Intraoperative Hemodynamic Instability","Postoperative Complication","Postoperative Delirium (POD)",[341,342,343,344],"Intraoperative Hypotension","Cardiopulmonary Bypass","Mean Arterial Pressure","Cohort Study","2026-07-28",{"date":293,"type":46},{"date":348,"type":46},"2025-04-26",{"date":350,"type":22},"2026-09-05",{"name":352,"class":53},"Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":373,"leadSponsor":375,"locationsCount":54},"100649702","phase-2-terbinafine-for-csa-aki-prevention-100649702","NCT07738328","Terbinafine for CSA-AKI Prevention","Terbinafine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged ≥18 and ≤75 years, without restriction on gender.\n* Patients with a definite clinical diagnosis scheduled for elective cardiac and macrovascular surgery with cardiopulmonary bypass (CPB) support, including but not limited to coronary artery bypass grafting (CABG), cardiac valve replacement\u002Frepair, structural heart disease surgery, aortic arch plasty, or combined procedures of the above surgeries.\n* Classified as high risk by AKI risk scoring system, with a total score ≥4 points.\n* The subject or their legal representative shall fully understand the purpose, procedures, potential risks and benefits of this study, and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* Patients with severe chronic renal insufficiency (eGFR \\\u003C 50 mL\u002Fmin\u002F1.73 m² or serum creatinine \\> 300 μmol\u002FL), or those receiving any form of renal replacement therapy (e.g., hemodialysis, peritoneal dialysis).\n* Pre-existing acute kidney injury.\n* Presence of chronic or active liver diseases, including decompensated liver cirrhosis, active viral hepatitis, autoimmune liver disease, etc.; or preoperative laboratory tests showing ALT\u002FAST ≥ 2 times the upper limit of normal (ULN).\n* Severe hematological diseases (preoperative white blood cell count \\\u003C 3.0 × 10⁹\u002FL, platelet count \\\u003C 80 × 10⁹\u002FL).\n* Uncontrolled active infections, or known immunodeficiency disorders (e.g., HIV infection, status post organ transplantation).\n* History of severe hypersensitivity to terbinafine or any excipients of its formulation.\n* Pregnant or lactating women, as well as women of childbearing potential who plan to conceive during the study and refuse to use effective contraception.\n* Participation in any other clinical trial of investigational drugs or medical devices within 3 months prior to screening.\n* Patients deemed inappropriate for enrollment in this study at the investigator's clinical discretion.","75 Years",{"count":362,"type":22},208,[66],"Primary Objective: To evaluate the efficacy and safety of perioperative oral terbinafine in reducing the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI).Secondary Objectives:To assess the effects of terbinafine on the severity of post-cardiac surgery AKI, length of hospital stay, and 30-day major adverse kidney events (MAKE30);To evaluate its impacts on biomarkers of renal injury and inflammation.",[28,157],[28,367,368,369],"Cardiac Surgery-Associated Acute Kidney Injury","Terbinafine","Randomized","2026-07-27",{"date":295,"type":46},{"date":297,"type":22},{"date":374,"type":22},"2028-05-01",{"name":376,"class":53},"Guangdong Provincial People's Hospital",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":54},"100649325","phase-4-a-prompt-restart-study-of-renin-angiotensin-system-inhibitors-after-acute-kidney-injury-100649325","NCT07734636","A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury","APRES-AKI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease)\n* RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr)\n* AKI in recovery (defined by a decrease in SCr by ≥0.3mg\u002FdL from peak)\n\nExclusion Criteria:\n\n* RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis)\n* Ongoing dialysis requirement\n* Pregnant or breastfeeding\n* Prisoner\n* Palliative or hospice care involvement\n* Unable to consent\n* No enteral route of medication administration\n* Clinician judgment",{"count":385,"type":22},60,[93],"The goal of this pilot clinical trial is to learn if early restart of renin-angiotensin system inhibitor (RASi) medications is feasible and well-tolerated in hospitalized patients with acute kidney injury (AKI). Researchers will compare early RASi restart to usual care.\n\nStudy participants will restart RASi per study protocol, obtain a lab test in 1-2 weeks if RASi restarted in the hospital and not collected as part of routine care, and answer questions at the 90-day follow-up.",[28],[33],"2026-07-23",{"date":293,"type":46},{"date":192,"type":22},{"date":394,"type":22},"2029-03",{"name":396,"class":53},"University of California, San Francisco",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":413,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":426},"100535429","fluid-removal-guided-by-vexus-score-with-usual-care-in-patients-with-acute-kidney-injury-after-cardiac-surgery-100535429","NCT06251713","Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery","Feasibility of a Randomised Trial Comparing a Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery: a Pilot Randomised Trial.","VeXUS","Inclusion Criteria:\n\n* Intensive care unit admission within 72 hours of cardiac surgery with extracorporeal circulation\n* Acute kidney injury defined by KDIGO criteria\n* Vasoactive inotropic score \\\u003C45 and capillary refill time \\\u003C3s\n* Informed written consent\n\nExclusion Criteria:\n\n* Hypokalaemia \\\u003C3.5mmol\u002FL\n* Hyponatremia\\\u003C125mmol\u002FL\n* Hypernatremia \\>145mmol\u002FL\n* Metabolic alkalosis with pH \\>7.50\n* Impossibility to measure capillary refill time\n* Chronic liver disease\n* Cirrhosis with portal hypertension\n* Known thrombus of the inferior vena cava\n* Mechanical circulatory assistance (ECMO or mono left ventricular assistance)\n* Severe pre-operative chronic kidney disease (GFR \\\u003C 30mL\u002Fmin\u002F1.73m2)\n* Need for renal replacement therapy anticipated by the attending physician within 24 hours\n* Known hypersensitivity to Furosemide and\u002For hydrochlorothiazide\n* Severe allergy to wheat\n* Patient already included in another interventional study with an exclusion period still in progress\n* Pregnant, breast-feeding or women of childbearing age without suitable contraception\n* Patients under guardianship, curatorship or safeguard of justice\n* Patients under psychiatric care\n* Patients not affiliated to a social security scheme or beneficiaries of a similar scheme","85 Years",{"count":407,"type":22},40,[25],"Acute kidney injury affects more than 30% of patients after cardiac surgery, and is associated with an excess in mortality. There is a clinical continuum between acute kidney injury (transient if \\\u003C48h, persistent if \\>48h), the development of acute kidney and chronic renal failure. Each of these entities characterising renal recovery is associated with an increase in long-term morbidity and mortality. Fluid management in patients with acute kidney injury is challenging, as both hypovolaemia and hypervolaemia are detrimental. Venous congestion (reflecting intravascular hypervolaemia), is a well-established haemodynamic factor contributing to acute kidney injury after cardiac surgery. An ultrasound score, based on the venous doppler pattern explored in intra-abdominal organs, has recently been developed and is a better predictor of acute kidney injury than central venous pressure. Whether using the VeXUS score to guide fluid removal in haemodynamically stabilised patients could promote renal recovery after acute kidney injury remains to be investigated.\n\nBefore designing a large randomised trial to test such a strategy, its feasibility in a pilot randomised trial is assessed.",[28,336,411,412],"Venous Congestion","Hemodynamic Stability",[33,414,411,415,416,417],"Cardiac surgery","VeXUS score","diuretic","fluid removal",{"date":419,"type":46},"2026-07-24",{"date":421,"type":46},"2024-07-31",{"date":423,"type":22},"2027-07",{"name":425,"class":53},"Hospices Civils de Lyon",2,{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":54},"100609285","phase-2-biomarker-and-renal-angina-validation-to-assess-heart-kidney-outcomes-after-amino-acid-therapy-100609285","NCT07212595","Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy","BRAVE-HEART","Inclusion Criteria:\n\n* Expected to be at high risk of developing acute kidney injury after cardiac surgery based on Age, The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) score, and anticipated cardiopulmonary bypass time\n* Age less than or equal to 18 years\n* Weight greater than or equal to 5 kilograms\n\nExclusion Criteria:\n\n* Preoperative extracorporeal organ support\n* History of chronic kidney disease\n* Known or suspected inborn errors of amino acid metabolism\n* Known hypersensitivity to amino acids\n* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \\> 3 times the upper limit of normal for age\u002Fgender\n* Preterm infants less than 6 months of age who were born at less than 36 weeks gestational age\n* Anuria at the time of randomization\n* Expected use of total parental nutrition (TPN) within the first 72 hours post-operatively",{"count":435,"type":22},30,[66],"The goal of the BRAVE-HEART study is to learn if an amino acid infusion can reduce the risk of developing acute kidney injury after cardiac surgery in children. The main questions it aims to answer are:\n\n1. Does an amino acid infusion decrease the number of participants with acute kidney injury?\n2. Does an amino acid infusion decrease the number of days that participants are on a ventilator after cardiac surgery?\n\nResearchers will compare amino acids to a placebo (a look-alike substance that contains no drug) to see if amino acids decrease the number of participants with acute kidney injury.\n\nParticipants will receive an amino acid or placebo infusion for up to 72 hours starting during cardiac surgery and only while in the operating room or the intensive care unit.",[28,439],"Mechanical Ventilation",[441,442,28,443],"Cardiac Bypass","Pediatric","Amino Acids","2026-07-22",{"date":419,"type":46},{"date":447,"type":46},"2026-07-08",{"date":449,"type":22},"2027-12-31",{"name":451,"class":53},"Dana Fuhrman",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":469,"locationsCount":54},"100648376","treatment-costs-of-kidney-injury-in-patients-having-heart-surgery-in-the-uk-100648376","NCT07719569","Treatment Costs of Kidney Injury in Patients Having Heart Surgery in the UK","Treatment Costs of Acute Kidney Injury in Patients Undergoing Cardiac Surgery in the UK: A Retrospective Study","Cost-AKI","Inclusion Criteria:\n\n* Underwent elective or in-house urgent cardiac surgery at the Royal Wolverhampton NHS Trust between 1st January 2013 and 31st December 2025, excluding those who had surgery during 2020 and 2021 due to the confounding effect of COVID-19 on acute kidney injury incidence.\n* Cardiopulmonary bypass (CPB) was utilised during the cardiac surgical procedure.\n* A complete minimum dataset is available within the study databases, comprising: age, sex, history of diabetes, left ventricular ejection fraction (LVEF), surgical priority, pre-operative haemoglobin and serum creatinine (SCr) levels, type of cardiac surgery performed, CPB duration, EuroSCORE or logistic EuroSCORE, renal replacement therapy (RRT) use, and post-operative day 1 and\u002For day 2 and\u002For day 3 SCr values.\n\nExclusion Criteria:\n\n* The procedure was performed as an emergency surgery.\n* Required data fields are incomplete or unavailable.\n* Surgery was performed off-pump, without the use of cardiopulmonary bypass.\n* The patient was dialysis-dependent prior to surgery.\n* The patient had a pre-operative estimated glomerular filtration rate (eGFR) of less than 20 mL\u002Fmin\u002F1.73 m².\n* The cardiac procedure required deep hypothermic circulatory arrest (DHCA).\n* The patient has exercised their right to opt out of research data use.",{"count":461,"type":22},4600,"Single-centre retrospective analysis of prospectively collected data with propensity matched scoring groups (AKI v\u002Fs non-AKI). Data collection from databases (or their equivalent): PATS Dendrite, Electronic Medical Records, TD-web (results Portal), MedTrack (ICU database), iSite (Radiology), SPY (Long-term status)",[28],"2026-07-21",{"date":444,"type":46},{"date":172,"type":22},{"date":468,"type":22},"2027-04-01",{"name":470,"class":278},"The Royal Wolverhampton Hospitals NHS Trust",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":54},"100648398","fst-analysis-supporting-timely-therapy-and-risk-assessment-via-clinical-decision-support-for-kids-100648398","NCT07718464","FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for Kids","Furosemide Stress Test Implementation and Outcomes in Critically Ill Children at High Risk for Acute Kidney Injury: A Hybrid Study","FAST TRACK","Inclusion Criteria:\n\n* Admitted to the pediatric intensive care unit (PICU)\n* Renal Angina Index (RAI) greater than or equal to 8 (RAI+)\n* Urine NGAL greater than or equal to 150 ng\u002FmL (NGAL+)\n\nExclusion Criteria:\n\n* Receipt of renal replacement therapy prior to PICU admission",{"count":480,"type":22},120,"The goal of this study is to learn whether adding a clinical decision support tool to the electronic medical record helps clinicians use the furosemide stress test in critically ill children at high risk for severe acute kidney injury (AKI). The main question it aims to answer is: Does implementing the decision support tool reduce fluid overload and help predict which children will receive dialysis?\n\nResearchers will identify children admitted to the pediatric intensive care unit who are at high risk for AKI using risk stratification and biomarker testing, then compare outcomes in the two years after the tool is introduced with the two years before.",[28,483,484],"Renal Replacement Therapy","Pediatric Intensive Care Unit",[486,487,488],"NGAL","Renal Angina Index","Furosemide Stress Test",{"date":444,"type":46},{"date":491,"type":46},"2026-05-27",{"date":493,"type":22},"2028-06",{"name":495,"class":53},"Children's Hospital Medical Center, Cincinnati",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":18,"minAge":504,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":507,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":521,"locationsCount":54},"100533759","phase-4-effect-of-a-furosemide-stress-test-guided-strategy-on-liberation-from-continuous-renal-replacement-therapy-in-critically-ill-patients-with-acute-kidney-injury-100533759","NCT06229990","Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury","Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury (FST-LIBERATE)","FST-LIBERATE","Inclusion Criteria:\n\n* Adult 20 year of age or older\n* Acute kidney injury (AKI) stage 3 according to Kidney Disease Improving Global Outcomes (KDIGO) classification with oliguria (urine \\\u003C400 ml\u002Fday)\n* Initiate CRRT in ICU (medical ICU, surgical ICU, cardiac care unit) for at least 48 hours (time for initiation and modality of CRRT can adjust by clinician)\n\nExclusion Criteria:\n\n* Use any inotropic drug (norepinephrine, epinephrine, dopamine, dobutamine)\n* Blood urea nitrogen (BUN) \\>80 mg\u002FdL\n* Serum K \\\u003C3.5 or \\>5 mmol\u002FL\n* Arterial potential of Hydrogen (pH) \\\u003C7.3\n* Serum bicarbonate (HCO3) \\\u003C15 mmol\u002FL\n* Urine volume \\\u003C400 or \\>2,100 mL\u002Fday\n* Urine creatinine clearance (CrCl) at 6 hours \\>20 mL\u002Fmin\n* Previous chronic kidney disease (CKD) stage 5 or estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m2\n* Previous RRT within 14 days\n* Kidney transplantation\n* Obstructive etiology for AKI\n* Toxin\u002Fdrug that necessitates RRT\n* Allergy to furosemide\n* Moribund with expected death within 24 hours\n* Pregnancy","20 Years",{"count":506,"type":22},80,[93],"Currently, continuous renal replacement therapy (CRRT) is the main modality for renal support in critically ill patients with hemodynamic instability. Most studies have investigated the timing of RRT initiation. However, prolonged CRRT demonstrated the association of many unexpected events, such as catheter-related complications, catheter-related blood stream infection, hypotension, hypothermia, tachycardia, and atrial fibrillation. Up to now, there is a lack of evidence regarding the timing of withholding CRRT. The furosemide stress test (FST) is a tool that is easy to use and has more availability. The investigators aimed to apply FST to evaluate renal recovery compared with standard treatment in critically ill patients undergoing CRRT.",[28],[33,511,512,513,514],"Continuous renal replacement therapy","Furosemide stress test","Critical care","CRRT","2026-07-15",{"date":517,"type":46},"2026-07-16",{"date":519,"type":46},"2024-01-01",{"date":79,"type":22},{"name":522,"class":53},"Chiang Mai University",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":54},"100615374","doppler-evaluation-for-congestive-acute-kidney-injury-in-critical-illness-100615374","NCT07291778","Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness","The Impact of VeXUS-guided Fluid Management in ICU Populations on Renal Function","DECONGEST-AKI","Inclusion Criteria:\n\n* Adults (≥18 years old)\n* Admitted to the MICU, MCCU, or CCU within 24 hours of admission\n* Acute kidney injury (AKI) (based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria)\n* Adequate acoustic windows for a complete VExUS scan\n\nExclusion Criteria:\n\n* \\\u003C 18 years old\n* pregnant women\n* End-stage renal disease (ESRD) or prior renal transplant\n* Acute tubular necrosis (ATN) defined by urinalysis (≥2+ protein, ≥2+ blood, ≥1 muddy brown cast, ≥1 RBC cast, or ≥1 dysmorphic RBC)'\n* Prior Whipple procedures\n* currently incarcerated",{"count":532,"type":22},100,[25],"This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.",[28,536],"VExUS",[536,538,28,539],"Fluid Management","ICU","2026-07-14",{"date":517,"type":46},{"date":543,"type":22},"2026-12-01",{"date":545,"type":22},"2028-12-01",{"name":547,"class":53},"University of Alabama at Birmingham",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":360,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":570},"100589463","phase-2-clinical-study-to-evaluate-the-efficacy-and-safety-of-mesenchymal-stromal-cells-amimestrocel--in-patients-with-acute-kidney-injury-100589463","NCT06954740","Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury","MSC-AKI-001","Inclusion Criteria:\n\n1. Aged between 18 and 75 years old; gender is not restricted.\n2. According to the 2023 KDIGO diagnostic criteria for acute kidney injury (AKI), including those that occur during the course of the disease in various patients with chronic kidney disease (CKD), AKI can be diagnosed if any of the following conditions is met:\n\n   ① The serum creatinine level increases by ≥ 26.5 μmol\u002FL within 48 hours;\n\n   ② The serum creatinine level increases by more than 1.5 times or higher than the baseline value within 7 days;\n\n   ③ The urine output decreases (\\\u003C 0.5 mL\u002Fkg\u002Fh) and persists for more than 6 hours; The baseline value of serum creatinine: The lowest creatinine value obtained in the outpatient department or ward within 3 months, and the longest time limit is the creatinine value within 1 year. If there is no such value, the serum creatinine can be estimated using the MDRD equation under the assumption that the baseline eGFR is 75 ml\u002Fmin\u002F1.73m².\n3. .Ability to give informed consent.\n\nExclusion Criteria:\n\n1. Post-renal AKI.\n2. Acute kidney injury caused by glomerular diseases such as rapidly progressive glomerulonephritis, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, anti-glomerular basement membrane antibody-mediated nephritis, vasculitis, cryoglobulinemia, thrombotic microangiopathy, etc.\n3. Hemodynamic instability.\n4. Severe cardiovascular diseases.\n5. Severe pulmonary dysfunction.\n6. A history of intracerebral hemorrhage or cerebral infarction within the past six months.\n7. Subjects with abnormal laboratory indicators: AST or ALT \\> 5 × upper limit of normal value (ULN); total bilirubin \\> 3 × ULN; white blood cell count \\\u003C 2000\u002FμL (2 × 10⁹\u002FL), hemoglobin \\\u003C 6 g\u002FdL (60 g\u002FL), neutrophils \\\u003C 1000\u002FμL (1 × 10⁹\u002FL), platelets \\\u003C 50000\u002FμL (50 × 10⁹\u002FL).\n8. Uncontrollable infection.\n9. Patients with active hepatitis B or hepatitis C virus infection, active tuberculosis, severe immunodeficiency diseases, human immunodeficiency virus (HIV) infection, etc.\n10. Received systemic immunosuppressants or glucocorticoid treatment for more than one week within 30 days before enrollment.\n11. Have received hemodialysis or peritoneal dialysis treatment.\n12. Have a history of hematopoietic stem cell transplantation or solid organ transplantation.\n13. Patients with a history of malignant tumor within the past 5 years.\n14. Life expectancy is less than 1 month.\n15. Those with a known history of severe allergy to component blood or blood products, or those with a history of allergy to heterologous proteins.\n16. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a fertility plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take contraceptive measures.\n17. Patients who participated in other interventional clinical trials within 1 month before enrollment.",{"count":246,"type":22},[66],"This trial is to evaluate the efficacy and safety of Amimestrocel (human umbilical cord mesenchymal stromal cells) in the treatment of AKI patients.",[28],[560,561],"mesenchymal stromal cells (MSCs)","acute kidney injury(AKI)","2026-07-12",{"date":540,"type":46},{"date":565,"type":46},"2025-06-10",{"date":567,"type":22},"2028-05-15",{"name":569,"class":53},"Chinese PLA General Hospital",6,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":578,"minAge":19,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":54},"100647167","early-kidney-injury-biomarkers-in-gynecologic-laparoscopic-surgery-100647167","NCT07704242","Early Kidney Injury Biomarkers in Gynecologic Laparoscopic Surgery","Comparative Analysis of Urinary NGAL and KIM-1 Levels in Predicting Subclinical Acute Kidney Injury Secondary to Pneumoperitoneum and Deep Trendelenburg Position in Gynecological Laparoscopic Surgery","Inclusion Criteria: Female participants aged 18 years or older. Scheduled for elective gynecological laparoscopic surgery. Expected duration of pneumoperitoneum of at least 90 minutes. Planned intraoperative Trendelenburg position of approximately 30° or 45°. Ability to provide written informed consent. -\n\nExclusion Criteria: Age younger than 18 years. Pre-existing chronic kidney disease (estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m² or serum creatinine above the institutional upper limit of normal).\n\nAcute kidney injury before surgery. History of kidney transplantation or renal replacement therapy. Active urinary tract infection. Pregnancy. Conversion from laparoscopic to open surgery. Intraoperative conditions requiring major deviation from the standardized anesthetic or surgical protocol.\n\nInability to provide written informed consent.\n\n\\-","FEMALE",{"count":246,"type":22},"This prospective observational study aims to evaluate early subclinical acute kidney injury associated with pneumoperitoneum and Trendelenburg positioning during gynecological laparoscopic surgery. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) levels will be measured and normalized to urinary creatinine. Biomarker changes will be compared between patients undergoing surgery in 30° and 45° Trendelenburg positions. The study seeks to determine whether these biomarkers can detect early renal injury before clinically significant changes in serum creatinine occur.",[28,582],"Subclinical Acute Kidney Injury",[486,584,585,586,587,28,588,589],"KIM-1","Gynecologic Laparoscopy","Pneumoperitoneum","Trandelenburg Position","Biomarker","Renal Injury","2026-07-09",{"date":515,"type":46},{"date":593,"type":22},"2026-08-01",{"date":595,"type":22},"2027-03-01",{"name":597,"class":53},"Medipol University",{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":625},"100550412","low-dose-intensity-vs-standard-dose-intensity-continuous-renal-replacement-therapy-in-critically-ill-patients-wisdom-100550412","NCT06446739","LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)","LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM): A Pilot Randomized Trial","WISDOM","Inclusion Criteria:\n\n* age ≥ 18 years\n* weight ≥ 55 kg\n* plan to initiate CRRT or within 24 hours of having started CRRT for AKI\n* expected to survive and receive CRRT for a duration of ≥ 48 hours\n* able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB).\n\nExclusion Criteria:\n\n* indication for sustained higher dose-intensity CRRT as designated by the attending clinicians\n* end-stage kidney disease receiving maintenance dialysis\n* receipt of any RRT for AKI during the current hospitalization\n* inability to comply with the requirements of the study protocol.",{"count":532,"type":22},[25],"An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive a continuous form of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.",[28,610],"Dialysis; Complications",[612,613,614,615,616],"acute kidney injury","continuous renal replacement therapy","dose-intensity","randomized trial","pilot feasibility","2026-07-07",{"date":590,"type":46},{"date":620,"type":46},"2024-11-14",{"date":622,"type":22},"2027-06",{"name":624,"class":53},"University of Alberta",10,{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":635,"conditions":636,"keywords":641,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":625},"100642154","volume-removal-intolerance-during-net-ultrafiltration-in-acute-kidney-injury-patients-100642154","NCT07643597","Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients","VINKO","Inclusion Criteria:\n\n* Age ≥18 years\n* Admission to an Intensive Care Unit\n* Acute kidney injury according to KDIGO criteria\n* Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration\n* Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team\n\nExclusion Criteria:\n\n* Chronic kidney replacement therapy prior to ICU admission\n* Pregnancy\n* Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period\n* Inability to perform hemodynamic or perfusion assessment\n* Extracorporeal membrane oxygenation (ECMO)\n* Refusal to participate in the study",{"count":634,"type":22},128,"Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process.\n\nThe purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance.\n\nThe investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.",[28,637,638,639,640],"Fluid Overload","Fluid Overload in Dialysis Patients","Critical Illness","Renal Replacement Therapy for Acute Kidney Injury in ICU",[642,643,644,645,646,637,536,647],"Net Ultrafiltration","Continuous Renal Replacement Therapy","Fluid Removal","Ultrafiltration Intolerance","Tissue Hypoperfusion","Point-of-Care Ultrasound","2026-07-05",{"date":447,"type":46},{"date":651,"type":46},"2026-07-06",{"date":653,"type":22},"2027-12-01",{"name":655,"class":53},"Hospital Las Higueras"]